安慰剂
痴呆
临床终点
阿尔茨海默病
疾病
临床痴呆评级
临床试验
内科学
生物标志物
随机对照试验
认知
肿瘤科
医学
病理
精神科
替代医学
化学
生物化学
作者
Samantha Budd Haeberlein,Paul Aisen,Frederik Barkhof,Spyros Chalkias,Tianle Chen,Sarah Cohen,Gersham Dent,Oskar Hansson,Katie Harrison,Christian von Hehn,Takeshi Iwatsubo,Craig Mallinckrodt,Cath Mummery,Kumar Kandadi Muralidharan,Ivan Nestorov,Laura Nisenbaum,Raj Rajagovindan,LeAnne Skordos,Y. Tian,Christopher H. van Dyck
出处
期刊：JPAD
[SERDI]
日期：2022-03-15
卷期号：9 (2): 197-210
被引量：1124
标识
DOI：10.14283/jpad.2022.30
摘要
Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
陈末
无极微光
小杭76
xxfsx
Criminology34
pluto
小青椒
eric888
avalanche
hhhg
yznfly
Mic
ccm
WB87
iNk
tuanheqi
子车茗
寻道图强
Zx_1993
kentonchow
ZOE
彭于彦祖
sevenhill
皖公网安备34019202002308
